[An analysis of the causes of low-efficacy treatment in type-2 diabetes mellitus using sulfonylurea derivatives].
Peroral sugar-reducing agents have come to be routinely used in the treatment of type-II diabetes mellitus. The chief representatives of this group of drug preparations are derivatives of sulfonylurea. However, following a certain period of time of effective utilization of sulfanilamides, there develops secondary sulfanilamide resistance. An analysis has been performed of causes of low effectiveness of sulfonylurea derivatives in the treatment of type-II diabetes mellitus. Errors in the policy of treating diabetes mellitus with the above drug preparations are analysed as are causes of secondary insulin dependence.
Gendeleka
G F
GF
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008508:Medication Errors; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D017211:Treatment Failure; D016312:Treatment Refusal
D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds